Suchen
Pharming Group NV
PHARZur Watchlist hinzufügen
13.770USD
+0.050+0.36%
Handelsschluss 07/02, 13:00（ET）Kurse um 15 Minuten verzögert
0.00Marktkapitalisierung
--KGV TTM
mehr Informationen über Pharming Group NV Unternehmen
Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.
Pharming Group NV Informationen
BörsenkürzelPHAR
Name des UnternehmensPharming Group NV
IPO-datumJul 02, 1998
CEOChouraqui (Fabrice)
Anzahl der mitarbeiter- -
WertpapierartDepository Receipt
Geschäftsjahresende- -
AddresseDarwinweg 24
StadtLEIDEN
BörseNASDAQ OMX - NASDAQ BASIC
LandNetherlands
Postleitzahl2333 CR
Telefon31715247400
Websitehttps://www.pharming.com/
BörsenkürzelPHAR
IPO-datumJul 02, 1998
CEOChouraqui (Fabrice)
Führungskräfte von Pharming Group NV
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Stephen (Steve) Toor
Mr. Stephen (Steve) Toor
Chief Commercial Officer
Chief Commercial Officer
--
--
Mrs. Mireille Sanders
Mrs. Mireille Sanders
Chief Operations Officer
Chief Operations Officer
--
--
Ms. Barbara Yanni
Ms. Barbara Yanni
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Mark J. Pykett, M.D., Ph.D.
Dr. Mark J. Pykett, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Anurag Relan, M.D.
Dr. Anurag Relan, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Leonard Kruimer, CPA
Mr. Leonard Kruimer, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Jabine Van Der Meijs
Ms. Jabine Van Der Meijs
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Steven Baert
Mr. Steven Baert
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Ruud Van Outersterp
Mr. Ruud Van Outersterp
Chief Ethics and Compliance Officer
Chief Ethics and Compliance Officer
--
--
Dr. Richard Peters, M.D., Ph.D.
Dr. Richard Peters, M.D., Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Stephen (Steve) Toor
Mr. Stephen (Steve) Toor
Chief Commercial Officer
Chief Commercial Officer
--
--
Mrs. Mireille Sanders
Mrs. Mireille Sanders
Chief Operations Officer
Chief Operations Officer
--
--
Ms. Barbara Yanni
Ms. Barbara Yanni
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Mark J. Pykett, M.D., Ph.D.
Dr. Mark J. Pykett, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Anurag Relan, M.D.
Dr. Anurag Relan, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Leonard Kruimer, CPA
Mr. Leonard Kruimer, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Pharming Group NV?
Die fünf größten Anteilseigner von Pharming Group NV sind: Mr. Stephen (Steve) Toor
Wie viele Institutionen halten Anteile an Pharming Group NV (PHAR)?
Mit Stand vom 2026Q1 halten 22 Institutionen Anteile an Pharming Group NV, mit einem Gesamtmarktwert von etwa 135.73K, was 0.19% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um 61813.00 gestiegen.